ClinicalTrials.gg
CompletedNCT01076088Updated May 23, 2017Results posted

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

A Phase 3 interventional study of Sitagliptin 50 mg and Metformin 500 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
744
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
14th of 197
744 · median 102
Started
2010
with 22 others
Phase 3
74 of 198
none open now
Registered
82nd of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 82nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China. The primary hypothesis is that after 24 weeks, initial co-administration treatment with sitagliptin and metformin provided greater reduction in hemoglobin A1C (A1C) compared to initial treatment with sitagliptin alone and with metformin alone.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has type 2 diabetes mellitus
  • is male, a female who cannot have children, or a female who agrees to use during the study
  • is not on an antihyperglycemic agent (AHA) ( [A1C] 7.5-11.0%) or on oral single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)

Exclusion criteria

Exclusion Criteria:

  • Patient has type 1 diabetes mellitus or ketoacidosis
  • Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)
  • Patient is on a weight loss program not in the maintenance phase or on a weight loss medication
  • Patient has a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer
  • Patient is positive
  • Patient is pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
744 participants (actual)

Study arms

  • Experimental
    Sitagliptin 50 mg + metformin 500 mg

    Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.

    Drug: Sitagliptin 50 mg · Drug: Metformin 500 mg

  • Experimental
    Sitagliptin 50 mg + metformin 850 mg

    Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.

    Drug: Sitagliptin 50 mg · Drug: Metformin 850 mg

  • Active comparator
    Metformin 500 mg

    Metformin 500 mg twice daily for 24 weeks.

    Drug: Metformin 500 mg

  • Active comparator
    Metformin 850 mg

    Metformin 850 mg twice daily for 24 weeks.

    Drug: Metformin 850 mg

  • Experimental
    Sitagliptin 100 mg

    Sitagliptin 100 mg once daily for 24 weeks.

    Drug: Sitagliptin 100 mg

  • Placebo comparator
    Placebo

    Matching placebo tablets for 24 weeks.

    Drug: Placebo

Interventions

  • Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.

    Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®

  • Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.

    Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®

  • Sitagliptin 100 mg once daily for 24 weeks.

    Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®

  • DrugPlacebo

    Matching placebo tablets to sitagliptin or metformin for 24 weeks.

  • Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.

    Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 24

    A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24

    Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 6, 2014

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlacebo
Started122125126124120127
Completed111107109109104104
Not completed111817151623
Withdrew: Adverse event163233
Withdrew: Lost to follow-up110112
Withdrew: Non-compliance with study drug000100
Withdrew: Physician decision130110
Withdrew: Withdrawal by subject8814101117
Withdrew: Other protocol specified criteria000001

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (A1C) at Week 24

A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1C (A1C) at Week 24
Percent of glycosylated hemoglobinSitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850 mgSitagliptin 100 mgPlacebo
Change From Baseline in Hemoglobin A1C (A1C) at Week 24-1.67 (-1.92 to -1.43)-1.83 (-2.07 to -1.58)-1.29 (-1.54 to -1.04)-1.56 (-1.80 to -1.32)-0.99 (-1.24 to -0.75)-0.59 (-0.84 to -0.34)
Statistical analysis
  • Sitagliptin 50 mg + Metformin 850 mg vs Metformin 850 mg · ANCOVA · p = 0.087 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.27 · 95% CI -0.58 to 0.04The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 850 mg vs Sitagliptin 100 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.84 · 95% CI -1.15 to -0.52The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 500 mg vs Metformin 500 mg · ANCOVA · p = 0.014 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.39 · 95% CI -0.69 to -0.08The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 500 mg vs Sitagliptin 100 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.68 · 95% CI -0.99 to -0.37The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 850 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -1.24 · 95% CI -1.55 to -0.93The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Metformin 850 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, metformin 850 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.97 · 95% CI -1.28 to -0.66The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 500 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -1.08 · 95% CI -1.39 to -0.78The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Metformin 500 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, metformin 500 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.70 · 95% CI -1.01 to -0.39The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 100 mg vs Placebo · ANCOVA · p = 0.011 (Pairwise comparison, sitagliptin 100 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.) · Difference in least squares mean: -0.40 · 95% CI -0.71 to -0.09The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 850 mg vs Metformin 850 mg · Regression, Robust · p = 0.008 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.36 · 95% CI -0.62 to -0.09The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 850 mg vs Sitagliptin 100 mg · Regression, Robust · p = <0.001 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.87 · 95% CI -1.13 to -0.60The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 500 mg vs Metformin 500 mg · Regression, Robust · p = 0.007 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.36 · 95% CI -0.63 to -0.10The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 500 mg vs Sitagliptin 100 mg · Regression, Robust · p = <0.001 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.61 · 95% CI -0.88 to -0.35The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 850 mg vs Placebo · Regression, Robust · p = <0.001 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -1.25 · 95% CI -1.52 to -0.99The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Metformin 850 mg vs Placebo · Regression, Robust · p = <0.001 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.90 · 95% CI -1.16 to -0.63The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 50 mg + Metformin 500 mg vs Placebo · Regression, Robust · p = <0.001 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -1.00 · 95% CI -1.26 to -0.74The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Metformin 500 mg vs Placebo · Regression, Robust · p = <0.001 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.64 · 95% CI -0.90 to -0.37The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
  • Sitagliptin 100 mg vs Placebo · Regression, Robust · p = 0.004 (Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.) · Difference in least squares mean: -0.39 · 95% CI -0.65 to -0.12The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.
SecondaryChange From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24

Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24
mg/dLSitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlacebo
Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24-97.05 (-109.01 to -85.09)-109.46 (-121.47 to -97.44)-65.67 (-77.76 to -53.58)-90.93 (-103.04 to -78.83)-48.11 (-60.37 to -35.85)-21.88 (-34.33 to -9.43)
Statistical analysis
  • Sitagliptin 50 mg + Metformin 850 mg vs Metformin 850 · ANCOVA · p = 0.017 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg.) · Difference in least squares mean: -18.52 · 95% CI -33.75 to -3.29The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Sitagliptin 50 mg + Metformin 850 mg vs Sitagliptin 100 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg) · Difference in least squares mean: -61.34 · 95% CI -76.61 to -46.07The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Sitagliptin 50 mg + Metformin 500 mg vs Metformin 500 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg) · Difference in least squares mean: -31.38 · 95% CI -46.49 to -16.28The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Sitagliptin 50 mg + Metformin 500 mg vs Sitagliptin 100 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg) · Difference in least squares mean: -48.94 · 95% CI -64.21 to -33.67The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Sitagliptin 50 mg + Metformin 850 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo) · Difference in least squares mean: -87.57 · 95% CI -102.87 to -72.27The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Metformin 850 vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, metformin 850 mg vs. placebo) · Difference in least squares mean: -69.05 · 95% CI -84.41 to -53.70The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Sitagliptin 50 mg + Metformin 500 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo) · Difference in least squares mean: -75.17 · 95% CI -90.47 to -59.87The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Metformin 500 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, metformin 500 mg vs. placebo) · Difference in least squares mean: -43.79 · 95% CI -58.99 to -28.58The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
  • Sitagliptin 100 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 100 mg vs. placebo) · Difference in least squares mean: -26.23 · 95% CI -41.62 to -10.84The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLSitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-39.38 (-46.29 to -32.47)-47.74 (-54.73 to -40.75)-33.66 (-40.66 to -26.66)-39.63 (-46.50 to -32.76)-21.86 (-28.92 to -14.80)-11.93 (-18.94 to -4.92)
Statistical analysis
  • Sitagliptin 50 mg + Metformin 850 mg vs Metformin 850 · ANCOVA · p = 0.069 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg) · Difference in least squares mean: -8.11 · 95% CI -16.86 to 0.64The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Sitagliptin 50 mg + Metformin 850 mg vs Sitagliptin 100 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg) · Difference in least squares mean: -25.88 · 95% CI -34.72 to -17.04The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Sitagliptin 50 mg + Metformin 500 mg vs Metformin 500 mg · ANCOVA · p = 0.198 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg) · Difference in least squares mean: -5.72 · 95% CI -14.44 to 3.00The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Sitagliptin 50 mg + Metformin 500 mg vs Sitagliptin 100 mg · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg) · Difference in least squares mean: -17.53 · 95% CI -26.33 to -8.72The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Sitagliptin 50 mg + Metformin 850 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo.) · Difference in least squares mean: -35.81 · 95% CI -44.56 to -27.06The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Metformin 850 vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, metformin 850 mg vs. placebo.) · Difference in least squares mean: -27.70 · 95% CI -36.40 to -19.00The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Sitagliptin 50 mg + Metformin 500 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo.) · Difference in least squares mean: -27.45 · 95% CI -36.18 to -18.73The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Metformin 500 mg vs Placebo · ANCOVA · p = <0.001 (Pairwise comparison, metformin 500 mg vs. placebo.) · Difference in least squares mean: -21.73 · 95% CI -30.42 to -13.04The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.
  • Sitagliptin 100 mg vs Placebo · ANCOVA · p = 0.027 (Pairwise comparison, sitagliptin 100 mg vs. placebo.) · Difference in least squares mean: -9.93 · 95% CI -18.72 to -1.14The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 50 mg + Metformin 500 mg—0/122 (0%)9/122 (7.4%)
Sitagliptin 50 mg + Metformin 850 mg—0/125 (0%)14/125 (11.2%)
Metformin 500 mg—1/126 (0.8%)8/126 (6.3%)
Metformin 850—1/124 (0.8%)13/124 (10.5%)
Sitagliptin 100 mg—3/120 (2.5%)6/120 (5%)
Placebo—1/126 (0.8%)4/126 (3.2%)
Most frequent serious events
Most frequent serious events
EventSitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlacebo
Coagulation time shortenedInvestigations0/1220/1250/1260/1241/1200/126
Transaminases increasedInvestigations0/1220/1250/1260/1241/1200/126
Cerebral infarctionNervous system disorders0/1220/1250/1260/1241/1200/126
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1220/1250/1261/1240/1200/126
Thoracic vertebral fractureInjury, poisoning and procedural complications0/1220/1250/1261/1240/1200/126
Subarachnoid haemorrhageNervous system disorders0/1220/1250/1261/1240/1200/126
CoagulopathyBlood and lymphatic system disorders0/1220/1250/1260/1240/1201/126
Femur fractureInjury, poisoning and procedural complications0/1220/1251/1260/1240/1200/126
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1220/1250/1260/1240/1201/126
Lung infectionInfections and infestations0/1220/1250/1260/1240/1201/126
Most frequent other events
Most frequent other events
EventSitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlacebo
DiarrhoeaGastrointestinal disorders3/1224/1254/1269/1242/1204/126
NauseaGastrointestinal disorders2/1228/1251/1264/1240/1200/126
HypoglycaemiaMetabolism and nutrition disorders4/1227/1253/1262/1244/1202/126

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlaceboTotal
Mean52.6 ± 11.352.4 ± 9.352.6 ± 9.553.0 ± 10.351.7 ± 10.253.6 ± 9.752.7 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlaceboTotal
Female375857494640287
Male856769757487457
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent of glycosylated hemoglobin)Sitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlaceboTotal
Mean8.46 ± 0.978.66 ± 0.958.69 ± 0.998.67 ± 1.088.74 ± 1.148.97 ± 1.058.70 ± 1.04
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mg/dL)Sitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlaceboTotal
Mean175.6 ± 40.6181.9 ± 43.0184.6 ± 46.8183.5 ± 47.7182.5 ± 44.0185.8 ± 47.3182.3 ± 45.0
2-hour post meal glucose (2-h PMG)
2-hour post meal glucose (2-h PMG)(mg/dL)Sitagliptin 50 mg + Metformin 500 mgSitagliptin 50 mg + Metformin 850 mgMetformin 500 mgMetformin 850Sitagliptin 100 mgPlaceboTotal
Mean292.7 ± 81.2292.9 ± 68.4303.2 ± 74.1298.8 ± 74.6297.7 ± 74.7308.3 ± 83.6299.0 ± 76.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, O'Neill EA, Golm GT, Engel SS, Kaufman KD, Shankar RR. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig. 2016 Sep;7(5):727-36. doi: 10.1111/jdi.12511. Epub 2016 May 19. PubMed 27181998 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Dec 2012, 25 months.

Results were first posted in Feb 2014, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2010
First posted
Feb 25, 2010
StartActual
Nov 15, 2010
Primary completionActual
Dec 24, 2012
CompletionActual
Dec 24, 2012
Results first posted
Feb 6, 2014
Last update
May 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01076088
Responsible party
Sponsor
First posted
Feb 25, 2010
Start date
Nov 15, 2010
Primary completion
Dec 24, 2012
Completion
Dec 24, 2012
Results posted
Feb 6, 2014
Last update
May 23, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion